Table 3 Antiretroviral drug regimens ongoing before anti HCV treatment start.

From: HIV tropism switch in archived DNA of HIV-HCV subjects successfully treated with direct-acting antivirals for HCV infection

Antiretroviral therapy regimen

Patients, n (%)

2 NRTI + 1 NNRTI

13 (26.5%)

2 NRTI + InSTI

8 (16.3%)

1 NRTI + InSTI

7 (14.3%)

2 NRTI + 1 PI (/PIr)

7 (14.3%)

PI (/PIr) + InSTI

6 (12.2%)

Othera

4 (8.2%)

1 NRTI + 1 PI (/PIr)

2 (4.1%)

1 PI

2 (4.1%)

  1. For each drug combination are reported the absolute number of patients treated and the percentage respect to the total number of patients.
  2. NNRTI non-nucleoside reverse transcriptase inhibitor, PI protease inhibitor, Pir ritonavir boosted protease inhibitor, InSTI integrase strand-transfer inhibitor, NRTI nucleoside reverse transcriptase inhibitor, MRV maraviroc.
  3. aOther: MRV + INSTI + NRTI (1 pt); 1 PI + 1NNRTI (1 pt); 2 NRTI + MRV (1 pt); 1 NNRTI + INSTI (1 pt).
Back to article page